ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Protocol ID
APG-115-US-002
Condition/s
Melanoma
Solid tumours
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Sponsor
Ascentage Pharma Group Inc.
Collaborators
Merck Sharp & Dohme Corp.
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Years and older
International registry ID's
NCT03611868
Back to Registry
Study Title APG-115-US-002: A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Protocol ID APG-115-US-002
Disease (Sub Disease) Melanoma
Solid tumours
Diagnosis Stage New Diagnosis
Relapse/Refractory
Sponsor Ascentage Pharma Group Inc.
Collaborators Merck Sharp & Dohme Corp.
Links https://clinicaltrials.gov/ct2/show/NCT03611868
Trial Status Closed to Recruitment
Trial Open Date 29/08/2018
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Years and older
International registry ID's NCT03611868

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.